NCT04581408View on ClinicalTrials.gov

Mutation-specific Therapy for the Long QT Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

April 15, 2025

Study Completion Date

April 15, 2025

Conditions
Long QT Syndrome
Interventions
DRUG

Lumacaftor / Ivacaftor, Orkambi® Oral Tablet

"Total daily dose: 800 mg of Lumacaftor and 500 mg of Ivacaftor.~Duration of treatment: according to the clinical conditions of the patient and based on the response to the drugs: up to a maximum of 7 days"

Trial Locations (1)

20149

Istituto Auxologico Italiano, Ospedale San Luca, Milan

All Listed Sponsors
lead

Istituto Auxologico Italiano

OTHER